ECONOMIC IMPACT OF BIOLOGICAL TREATMENT OPTIMISATIONS IN RHEUMATOLOGICAL AND DERMATOLOGICAL DISEASES

M.D. GIL-SIERRA[1], M.D.P. BRICEÑO CASADO[2], C. MORENO-RAMOS[1], M.A. BLANCO-CASTAÑO[1], C.M. CUADROS-MARTINEZ[3].
[1]HOSPITAL UNIVERSITARIO DE PUERTO REAL, PHARMACY, PUERTO REAL, SPAIN.
[2]HOSPITAL UNIVERSITARIO DE JEREZ DE LA FRONTERA, HOSPITAL PHARMACY, JEREZ DE LA FRONTERA CÁDIZ, SPAIN.
[3]HOSPITAL UNIVERSITARIO JEREZ DE LA FRONTERA, PHARMACY, JEREZ DE LA FRONTERA, SPAIN

Section 4: Clinical Pharmacy Services | **4CPS-029**

BACKGROUND

Appropriate **optimisation** of **biologic agents** in immune-mediated inflammatory diseases can improve treatment **efficiency** by decreasing number of drug administrations**.**

AIM

To estimate **economic impact** of **optimising** the use of etanercept and adalimumab in patients with immune-mediated **dermatological and rheumatological** diseases.

MATERIAL AND METHODS

Descriptive retrospective study between November 2021 and September 2022

Patients → Patients with **psoriasis**, **spondyloarthritis**, **rheumatoid arthritis** and **psoriatic arthritis** treated with etanercept or adalimumab therapies for at least **6 months**

DATA: Electronic medical history and Farmatools® application

- Medical departments.
- Drugs
- Biochemical tests
- Pharmaceutical interviews
- serum drugs levels and anti-drug antibodies

Therapy optimizations

Optimised therapies were treatments with **extended dosing** regimens or treatment discontinuations due to adequate pathology control. Therapy optimizations applied according to a multidisciplinary protocol of clinical decisions based on:

- Biochemical tests (serum drug levels and anti-drug antibodies)
- Interviews patients' perception of disease course
- Medical criteria.

Economic impact

Savings from biological therapy optimizations: difference between costs of real doses used with optimized regimens and hypothetical costs with doses used prior to treatment optimizations. The **number of decreased drug administrations** was estimated

RESULTS

- **Total Patients:** 256 (182 of Internal Medicine department and 74 of Dermatology)
- **Distribution of drugs:** 171 patients received etanercept and 85 adalimumab.
- **Biochemical test and pharmaceutical interviews:** 258 (2 patients required 2 biochemical test and 2 pharmaceutical interviews).
- **Serum drug levels:** outside the optimal therapeutic ranges of drugs in 71.6% of cases.
- **Anti-drug antibodies:** 15 patients.
- **Treatment optimizations:** 115 patients [86 (74.8%) of Internal Medicine department and 29 (25.2%) of Dermatology].

Economic impact

Total economic savings associated with optimization of biological therapies: 68804.96 €
- **Internal Medicine department:** 53169,58€
- **Dermatology:** 15635.38€

Average monthly savings for these treatment optimizations: 6255 €/month

Number of drug administrations avoided: 777.

CONCLUSION

The **optimization** of **etanercept** and **adalimumab** regimens in our patients with **immune-mediated dermatological** and **rheumatological diseases** provided **high efficiency by decreasing the number of drug administrations**.

CONTACT DATA

E-mail: mangilsie@yahoo.com

eahp european association of hospital pharmacists — making the difference in medication